MÜGE ÖZSAN YILMAZ, Esra KARAKAS, Abdülrahim EREN, Gülen BURAKGAZİ, İhsan ÜSTÜN, Cumali GÖKÇE

Bromokriptin Direnci Olan Makroprolaktinomalı Bir Hastada Kabergolin Tedavisi ile Oluşan Gebelik: Olgu Sunumu

Bromokriptin ve kabergolin prolaktinoma tedavisinde kullanılan en yaygın dopamin agonistleridir. Dopamin agonistlerine direnç %10-15 civarında görülmektedir. Kliniğimize amenore ve baş ağrısı şikayeti ile başvuran 19 yaşında kadın hastaya yapılan tetkikler sonucu makroprolaktinoma tanısı konuldu. Başlangıç tedavisine kabergolin ile yanıt alınan hastanın takibinde gebelik istemi olması nedeniyle ilacı kesilip bromokriptin tedavisine geçildi. Bromokriptin 15 mg/gün yaklaşık 1 yıl kullanan hastada tedaviye cevapsızlık görüldüğü için bromokriptin direnci düşünülerek kabergolin tedavisine tekrar geçildi. Kabergolin tedavisi altında gebelik oluşan bu vakada, bromokriptin direncinin makroprolaktinoma takip ve tedavisini güçleştirebileceği ve direnç gelişen hastalarda alternatif ilaçlara geçilerek başarının sağlanabileceği vurgulanmak istenmiştir.

Pregnancy with Cabergoline Treatment in a Woman with Bromocriptine Resistant Macroprolactinoma: Case Report

Bromocriptine and cabergoline are the most preferred dopamine agonists in the therapy of prolactinomas. Primary resistance to dopamine agonists is usually seen in 10-15 % of the patients. Here, we described a case of a 19 year-old woman who was presented with amenorrhea and headache and then was diagnosed with macroprolactinoma. She was initially treated with cabergoline with a perfect response. We had switched cabergoline to bromocriptine because of the desire for pregnancy. After one year of 15 mg/day of bromocriptine treatment, the patient reported irregular menses with elevated prolactin levels. There with we changed bromocriptine to cabergoline because the cabergoline response was perfect at the beginning. We would like to emphasize that the resistance to bromocriptine therapy is not uncommon and may complicate the follow up of the patients with prolactinomas and in case of resistance, it is important to keep in mind to switch agents.

PDF

___

Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary 2005; 8: 43-52.
Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989; 69: 500-509.
Sabuncu T, Arikan E, Tasan E, Hatemi H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med 2001; 40: 857-861.
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331: 904-909.
Pascal-Vigneron V, Weryha G, Bose M, Leclere J. Hyperprolactinemic amenorrhea: treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med 1995; 24: 754-757.
Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987; 65; 823-827.
Krupp P, Monka C, Richter K. The safety aspects of infertility treatments. In Program of the Second World Congress of Gynecology and Obstetrics, Rio de Janeiro, Brazil, 1988: p 9.
Auriemma RS, Perone Y, DiSarno A, et al. Results of a single- center 10-year observational survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 2013; 98: 372-379.
Wu ZB, Yu CJ, Su PZ, Zhuge QC, Wu JS, Zheng WM. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg 2006; 104: 54-61.
Caccavelli L, Feron F, Morange I, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine- resistant prolactinomas. Neuroendocrinology 1994; 60: 314-322.
Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline hyperprolactinemia: therapeutic strategy. J Clin Endocrinol Metab 2001; 86: 5256- 5261. with clinical definition, and
Gürlek A, Karavitaki N, Ansorge O, Wass J. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 2007; 156: 143-53.
Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997; 82: 876- 883.